Institution

Centre Hospitalier Universitaire de Bordeaux

Bordeaux, FranceWebsite

Also known as: CHU de Bordeaux · University Hospital of Bordeaux · CHU

774running trials
301closed trials
35,146publications (OpenAlex)

Running trials

Recruiting
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
NCT06485908· Phase 1/2· Assistance Publique Hopitaux De Marseille· Source
Not yet recruiting
The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
NCT07925359· Boston Scientific Corporation· Source
Not yet recruiting
What is the Role of the Exposome in Pulmonary Hypertension
NCT07172334· Poitiers University Hospital· Source
Not yet recruiting
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source
Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
Analysis of histological risk factors and biomarkers in paediatric retinoblastoma
2024-515962-15-00· Phase 2· Institut Curie· Source
Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Not yet recruiting
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
NCT07766109· Phase 4· University Hospital, Toulouse· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Not yet recruiting
A trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
2025-524836-21-00· Phase 2· AstraZeneca AB· Source
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
NCT07923656· University Hospital, Bordeaux· Source
Not yet recruiting
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
NCT07376447· iVascular S.L.U.· Source
Not yet recruiting
Patient-Perceived Symptoms at the Center of Obstructive Sleep Apnea (OSA) Management: Validation of the French Version of the Patient-Reported Apnea Questionnaire (PRAQ)
NCT07836062· University Hospital, Bordeaux· Source
Not yet recruiting
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
NCT07571954· iVascular S.L.U.· Source
Recruiting
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source
Not yet recruiting
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
NCT07845994· Phase 3· University Hospital, Angers· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Not yet recruiting
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
NCT07929740· Phase 1· Kura Oncology, Inc.· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
NCT07818356· Phase 4· University Hospital, Toulouse· Source
Not yet recruiting
Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
2026-526117-28-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source
Recruiting
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
NCT07700758· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial
2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source
Enrolling by invitation
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
NCT07729852· Phase 2· Alterity Therapeutics· Source
Not yet recruiting
A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence
2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source
Not yet recruiting
Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)
NCT07871227· University Hospital, Bordeaux· Source
Not yet recruiting
Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer
NCT07296042· GCS Ramsay Santé pour l'Enseignement et la Recherche· Source
Not yet recruiting
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
NCT07853105· Phase 1/2· University Hospital, Strasbourg, France· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
NCT07545512· University Hospital, Clermont-Ferrand· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment
2025-523307-29-00· Phase 3· AstraZeneca AB· Source
Recruiting
Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.
2026-526775-27-00· Phase 2· Laboratoires Kol· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Servier· Source
Not yet recruiting
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
2024-512763-32-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Creation of a Biological Collection of BRonchiaI and Pulmonary Tissues From Surgical wastE
NCT07780630· University Hospital, Bordeaux· Source

Showing 50 of 774.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers56 recruiting
Lung cancer48 recruiting
Acute myeloid leukaemia25 recruiting
Stroke25 recruiting
Colorectal cancer24 recruiting
Liver and biliary tract cancer24 recruiting
Acute lymphoblastic leukaemia18 recruiting
Myelodysplastic syndromes16 recruiting
Kidney cancer15 recruiting
Bladder cancer14 recruiting
Lupus (SLE)13 recruiting
Multiple myeloma13 recruiting
Myeloproliferative neoplasms13 recruiting
High blood pressure12 recruiting
Multiple sclerosis12 recruiting
Pancreatic cancer12 recruiting
COPD11 recruiting
Crohn's disease11 recruiting
Fatty liver disease (MASLD/MASH)11 recruiting
Head and neck cancer9 recruiting
Melanoma9 recruiting
Systemic sclerosis (scleroderma)9 recruiting
Rheumatoid arthritis8 recruiting
Diffuse large B-cell lymphoma7 recruiting
Gastric and oesophageal cancer7 recruiting
Heart failure7 recruiting
Immune thrombocytopenia (ITP)7 recruiting
Narcolepsy7 recruiting
Neuroendocrine tumours7 recruiting
Ulcerative colitis7 recruiting
Atrial fibrillation6 recruiting
Chronic kidney disease6 recruiting
Chronic lymphocytic leukaemia6 recruiting
Epilepsy6 recruiting
Follicular lymphoma6 recruiting
Obesity6 recruiting
Prostate cancer6 recruiting
Asthma5 recruiting
Brain aneurysm5 recruiting
Endometrial cancer5 recruiting
HIV5 recruiting
Idiopathic pulmonary fibrosis5 recruiting
Parkinson disease5 recruiting
Sarcoma5 recruiting
Sickle cell disease5 recruiting
Sjögren's disease5 recruiting
ANCA-associated vasculitis4 recruiting
Bronchiectasis4 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)4 recruiting
Congenital heart disease4 recruiting
Cystic fibrosis4 recruiting
Dermatomyositis and polymyositis (myositis)4 recruiting
Hodgkin lymphoma4 recruiting
Ovarian cancer4 recruiting
Pulmonary arterial hypertension4 recruiting
Alzheimer disease3 recruiting
Aortic stenosis3 recruiting
Cervical cancer3 recruiting
Chronic myeloid leukaemia3 recruiting
Coronary artery disease3 recruiting
Cushing's syndrome3 recruiting
Glioblastoma3 recruiting
IgA nephropathy3 recruiting
Mantle cell lymphoma3 recruiting
Mesothelioma3 recruiting
Myasthenia gravis3 recruiting
Neuroblastoma3 recruiting
Neuromyelitis optica (NMOSD)3 recruiting
Obstructive sleep apnoea3 recruiting
Ventricular tachycardia3 recruiting
Vitiligo3 recruiting
Amyloidosis2 recruiting
Aplastic anaemia2 recruiting
Cytomegalovirus infection2 recruiting
Gout2 recruiting
Hidradenitis suppurativa2 recruiting
Huntington's disease2 recruiting
Liver cirrhosis2 recruiting
Macular degeneration2 recruiting
Metastatic breast cancer2 recruiting
Multiple system atrophy2 recruiting
Osteoarthritis2 recruiting
Peripheral artery disease2 recruiting
Sarcoidosis2 recruiting
Type 1 diabetes2 recruiting
Type 2 diabetes2 recruiting
ALS (motor neurone disease)1 recruiting
Ankylosing spondylitis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Autism1 recruiting
Barrett's oesophagus1 recruiting
Down syndrome1 recruiting
Duchenne muscular dystrophy1 recruiting
Endometriosis1 recruiting
Fabry disease1 recruiting
Glaucoma1 recruiting
Haemophilia1 recruiting
Hepatitis B1 recruiting
Hepatitis C1 recruiting
Hypertrophic cardiomyopathy1 recruiting
Irritable bowel syndrome1 recruiting
Meningioma1 recruiting
Myocarditis1 recruiting
Osteoporosis1 recruiting
Primary biliary cholangitis1 recruiting
Spinal cord injury1 recruiting
Tourette syndrome1 recruiting
Triple-negative breast cancer1 recruiting
Tuberculosis1 recruiting

Closed trials

Not yet recruiting
Phase 2 Trial of TAK-755 for Acute Ischemic Stroke
2025-522734-31-00· Phase 2· Takeda Development Center Americas Inc.· Source
Completed
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC
2025-522867-13-00· Phase 2· Merus B.V.· Source
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· Phase 1· Eli Lilly and Company· Source
Completed
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
2024-519258-35-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Completed
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma
2024-515162-13-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01· Phase 3· Shanghai Junshi Biosciences Co. Ltd.· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Completed
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
NCT06563804· Phase 1/2· Institut De Recherches Internationales Servier IRIS· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Completed
N/A
2024-513121-22-00· Phase 2· Gilead Sciences Inc.· Source
Completed
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869· Phase 2· Novo Nordisk A/S· Source
Completed
Long-term Outcomes of Glaucoma Surgery in a Real-life Setting: the Agora Registry Study
NCT06829810· University Hospital, Bordeaux· Source
Withdrawn
Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study
NCT05314140· French Cardiology Society· Source
Completed
Translation and Validation of the French Version of the Sleep Regularity Questionnaire: a New Tool to Address the the Challenge of Sleep Health
NCT06727448· University Hospital, Bordeaux· Source
Completed
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source
Completed
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Active, not recruiting
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Exploring Long-term Risks and STI Prevalence in Pre-Exposure Prophylaxis Users in Gironde, France
NCT06600087· University Hospital, Bordeaux· Source
Completed
A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus
NCT06413511· Phase 1· Glaxosmithkline Research & Development Limited· Source
Completed
ALS Phase II Study of NX210c
NCT06365216· Phase 2· Axoltis Pharma· Source
Completed
A Study of TAK-861 in People With Narcolepsy Type 1
NCT06505031· Phase 3· Takeda· Source
Completed
Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA
2024-516028-33-01· Phase 3· Inst Medecine Epidemiologie Appliquee· Source
Completed
A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease
NCT06286046· Phase 2· Agios Pharmaceuticals Inc.· Source
Completed
Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)
NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Active, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· Phase 2· GCP-Service International West GmbH· Source
Completed
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783· Phase 2· Alkermes, Inc.· Source
Completed
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580· Phase 3· Vor Biopharma· Source
Completed
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
NCT05901194· Phase 1/2· Assistance Publique - Hôpitaux de Paris· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
2023-507207-66-00· Phase 3· Oculis Operations S.a.r.l.· Source
Completed
Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy
2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Completed
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
NCT06358950· Phase 2· Alkermes, Inc.· Source
Completed
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC
2023-505145-93-00· Phase 1/2· Alentis Therapeutics AG· Source
Completed
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006)
2023-505520-61-00· Phase 2/3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· Phase 3· Sanofi· Source
Recruiting
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311· Phase 3· medac GmbH· Source
Active, not recruiting
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159· Phase 2· Dianthus Therapeutics· Source
Active, not recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source
Completed
A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer
NCT04916002· Phase 2· Regeneron Pharmaceuticals Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· Phase 3· Amgen· Source
Active, not recruiting
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

Showing 50 of 301.

Registry name variants (92)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Centre Hospitalier Universitaire de Bordeaux
Pessac, New Aquitaine 33604
373 trials
Centre hospitalier Universitaire de Bordeaux
Bordeaux, 33076
356 trials
CHU de Bordeaux
Bordeaux, 33600
75 trials
CHU Bordeaux
Bordeaux, 33075
69 trials
Centre Hospitalier Universitaire De Bordeaux
Bordeaux Cedex, 33075
42 trials
Centre Hospitalier Universitaire De Bordeaux
Pessac Cedex, 33608
41 trials
CHU de Bordeaux
Pessac, 33604
21 trials
CHU Bordeaux
Pessac, 33604
19 trials
Bordeaux University Hospital
Bordeaux, 33076
16 trials
Centre Hospitalier Universitaire De Bordeaux
Talence, 33400
11 trials
University Hospital of Bordeaux
Bordeaux, Bordeaux 33300
11 trials
Bordeaux - CHU
Pessac
5 trials
University Hospital Of Bordeaux
Pessac Cedex, 33608
5 trials
CHU de Bordeaux - service de neurologie
Bordeaux
4 trials
CHU de Bordeaux - service de rhumatologie
Bordeaux
4 trials
University Hospital Bordeaux
Bordeaux, 33604
4 trials
CHU de Bordeaux - service de médecine interne
Pessac
3 trials
- NCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
  Contact: Estibaliz LAZARO
- NCT04800458Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
  Contact: Jean-François VIALLARD, Prof
- NCT04005638Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
  Contact: Jean-François VIALLARD, Prof
CHU de Bordeaux, service Hématologie Biologique
Bordeaux, 33600
3 trials
- NCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
  Contact: Alexandre GUY
- NCT06022328Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
  Contact: Olivier MANSIER
- NCT05499611Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia
University Hospital of Bordeaux
Pessac, 33604
3 trials
- NCT06735001Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
  Contact: Nicolas DERVAL
- NCT04681573Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
  Contact: Jérôme Boursier, MD-PHD
- NCT04867590A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus
  Contact: Arthur BERGER, Ph.D.
CHU Bordeaux
Talence, 33400
2 trials
- NCT07518186A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT04988555A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
  Contact: Arnaud Pigneux, MD
CHU Bordeaux (H Pellegrin)
Bordeaux
2 trials
- NCT07571954Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
  Contact: Xavier Barreau, Dr
- NCT07376447Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
  Contact: Xavier Barreau
CHU De Bordeaux
Bordeaux Cedex, 33075
2 trials
- NCT03212742Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients
- NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
CHU de Bordeaux - Centre Universitaire Pellegrin
Bordeaux, 33000
2 trials
- NCT03320252Endurant CHevAr New Indication Trial: ENCHANT
- NCT02988128Neurovascular Product Surveillance Registry
  Contact: Wouter Fabry
CHU de Bordeaux - Pellegrin
Bordeaux
2 trials
- NCT04760496Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour
- NCT04111211Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
CHU de Bordeaux - service de Médecine Interne et Maladies Infectieuses
Bordeaux
2 trials
- NCT06600087Exploring Long-term Risks and STI Prevalence in Pre-Exposure Prophylaxis Users in Gironde, France
- NCT05098704Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
  Contact: Fabrice BONNET, Prof
Bordeaux University Hospital - Pellegrin
Bordeaux, 33076
1 trial
- NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Centre Expert Hépatites Virales Aquitaine, CHU de Bordeaux
Bordeaux
1 trial
- NCT07038863Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
  Contact: Juliette Foucher, Dr
Centre Hospitalier Universitaire de Bordeaux (Adults only)
Pessac, Aquitaine 33600
1 trial
- NCT03394365A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  Contact: Data Protection Officer
Centre Hospitalier Universitaire de Bordeaux /ID# 222518
Pessac, Gironde 33604
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Centre Hospitalier Universitaire de Bordeaux /ID# 222696
Pessac, Gironde 33604
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Centre Hospitalier Universitaire de Bordeaux /ID# 253095
Pessac, Gironde 33604
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Centre Hospitalier Universitaire de Bordeaux /ID# 259298
Pessac, Gironde 33604
1 trial
- NCT05930275Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
CHU Bordeaux - Centre Francois Magendie
Pessac, New Aquitaine 33604
1 trial
- NCT06868485A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
  Contact: Principal Investigator
CHU Bordeaux (Expert center)
Bordeaux, 33000
1 trial
- NCT03453268Impact of Reducing Antihypertensive Treatment on Mortality in Frail Subjects With Low Systolic Blood Pressure (SBP).
CHU Bordeaux - GH Pellegrin
Bordeaux, 33000
1 trial
- NCT05387954PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
  Contact: Pauline Renou, MD
Chu Bordeaux - Hăpital Haut-Lăvăque
Pessac, 336600
1 trial
- NCT06644781A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
CHU Bordeaux - Service d'Oncologie Médicale
Pessac
1 trial
- NCT03815643Avelumab Program Rollover Study
CHU de Bordeaux
Bourdeaux, 33076
1 trial
- NCT04654000Rheopheresis as Adjuvant Treatment of Calciphylaxis
  Contact: M Yahsou Delmas, Dr
CHU de Bordeaux
Talence, 33404
1 trial
- NCT01658930Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
CHU de Bordeaux - CRCM pédiatrique
Bordeaux
1 trial
- NCT05937815Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
  Contact: Raphaël ENAUD
CHU de Bordeaux - Institut des maladies neurodégénératives de Bordeaux
Bordeaux, 33000
1 trial
- NCT05807373Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis - Part 2
CHU de Bordeaux, Laboratoire d'Hématologie
Pessac
1 trial
- NCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
  Contact: Victor-Emmanuel BRETT
CHU de Bordeaux, Laboratoire Hématologie
Bordeaux
1 trial
- NCT05419648Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
CHU de Bordeaux, Médecine Interne et maladies infectieuses
Bordeaux
1 trial
- NCT05419648Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
CHU de Bordeaux - service de médecine interne
Bordeaux
1 trial
- NCT04276701Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche -
Bordeaux, 33076
1 trial
- NCT03454646Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
  Contact: Jean-François DARTIGUES
CHU de Bordeaux, Service de Radiothérapie
Bordeaux
1 trial
- NCT05591534Endorectal Brachytherapy for Rectal Cancer
CHU de Bordeaux - Service d'Immunologie et Immunogénétique
Bordeaux
1 trial
- NCT03698071Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
CHU de Bordeaux, service d'Oncologie Médicale
Bordeaux
1 trial
- NCT06711770Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)
  Contact: Charlotte DOMBLIDES
CHU de Bordeaux, Service Hématologie Biologie
Pessac, 33604
1 trial
- NCT05839717Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
  Contact: Chloé JAMES
CHU de Bordeaux, Service Médecine Interne
Pessac, 33604
1 trial
- NCT05839717Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
  Contact: Jean-François VIALLARD
CHU de Bordeaux, Service Médecine Interne et Maladies Infectieuses
Bordeaux, 33000
1 trial
- NCT05839717Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
  Contact: Pierre DUFFAU
Chu de Bordeaux - Talence
Talence
1 trial
- NCT03293069Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique
Bordeaux, 33076
1 trial
- NCT05937828OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
  Contact: Nathalie ALADJIDI
CIC, CHU Bordeaux
Bordeaux
1 trial
- NCT04727489Study of the Genetic Factors Involved in Autism and Related Disorders
  Contact: Michael Fayon, MD., PhD.
Department of Neurology, CHU de Bordeaux - GH Pellegrin
Bordeaux
1 trial
- NCT05349006Azathioprine in MOGAD
  Contact: Aurélie RUET, Pr
Groupe Hospitaler Pellegrin, CHU De Bordeaux
Bordeaux
1 trial
- NCT05076149A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
Le Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33076
1 trial
- NCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
  Contact: Marie-Pierre Baudier
Le Centre Hospitalier Universitaire de Bordeaux
Talence, 33404
1 trial
- NCT07235514Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2
  Contact: Lise Laclautre
Neurology Department, CHU Bordeaux
Bordeaux, France 33000
1 trial
- NCT04693221Optimization of the Parameters of Vagal Nerve Stimulation
Pessac (CHU Bordeaux)
Pessac, Avenue Magellen 33600
1 trial
- NCT03183895Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study
Service de Médecine Physique & Réadaptation - CHU Bordeaux
Bordeaux, 33000
1 trial
- NCT07334977Synergistic Effect of Non-invasive Brain and Spinal Cord Stimulation
  Contact: Hélène Cassoudesalle, MD, PhD
Service d'endocrinologie, diabétoglogie et obésité pédiatrique, Bordeaux University Hospital
Bordeaux
1 trial
- NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
  Contact: Pascal BARAT, Professor of Medecine
Service de Rhumatologie - CHU de Bordeaux
Bordeaux
1 trial
- NCT02469753Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux
Pessac, 33604
1 trial
- NCT04707300Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
  Contact: Edouard FORCADE, PhD & MD
Unité d'Hémato-Oncologie Pédiatrique (UHOP) -CHU de Bordeaux - GH Pellegrin
Bordeaux
1 trial
- NCT07853105Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
  Contact: Jordane CHAIX
University Hospitals of Bordeaux
Bordeaux
1 trial
- NCT04339270Chronic Airway Disease, Mucus Rheology and Exacerbations
  Contact: Maéva Zysman, MD, PhD (principal investigator)
Bordeaux - CHU
Bordeaux, 33076
Bordeaux University Hospital - Pellegrin (Site 0806)
Bordeaux, Gironde 33076
Bordeaux University Hospital - Pellegrin (Site 3105)
Bordeaux, Aquitaine 33076
Bordeaux University Hospital - Pellegrin (Site 3605)
Bordeaux, Gironde 33076
Bordeaux University Hospital - Pellegrin (Site 4105)
Bordeaux, Aquitaine 33076
Centre Hospitalier Universitaire Bordeaux
Bordeaux
Centre Hospitalier Universitaire de Bordeaux
Bordeau
Centre Hospitalier Universitaire de Bordeaux /ID# 162558
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 207883
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 220989
Pessac, Gironde 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 230347
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 244953
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 252749
Pessac, Gironde 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 265721
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 278419
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux /ID# 279001
Pessac, New Aquitaine 33604
Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie
Bordeaux, 33000
CHU Bordeaux - Hôpial Saint André
Bordeaux
CHU Bordeaux /ID# 159704
Pessac, 33600
Chu de Bordeaux - Hăpital Haut-Lăvăque
Pessac, 33604
CHU de Bordeaux;Service d?endocrinologie, diabétologie et nutrition
Pessac, 33604
CHU de Bordeaux - Service d'Oncologie
Bordeaux
CHU de Bordeaux (Site # 0812)
Bordeaux, 33075
Department of Nephrology, University Hospital of Bordeaux
Bordeaux, 33000
Groupe SUD-Haut-Lévêque - Centre Hospitalier Universitaire de Bordeaux
Pessac, New Aquitaine 33604

Conditions

Diseases this institution publishes on or runs trials for.

Atrial fibrillation56 works · 12 trials
Systemic sclerosis (scleroderma)38 works · 21 trials
Acute myeloid leukaemia32 works · 56 trials
Crohn's disease23 works · 17 trials
Multiple myeloma23 works · 42 trials
Congenital heart disease22 works · 5 trials
Kidney cancer22 works · 32 trials
Cystic fibrosis20 works · 9 trials
Macular degeneration17 works · 5 trials
Ventricular tachycardia16 works · 4 trials
Atopic dermatitis (eczema)16 works · 13 trials
Pulmonary arterial hypertension15 works · 9 trials
Hodgkin lymphoma14 works · 11 trials
Multiple system atrophy11 works · 7 trials
Myelodysplastic syndromes11 works · 34 trials
Bronchiectasis10 works · 5 trials
Vitiligo10 works · 13 trials
Cushing's syndrome9 works · 4 trials
Cytomegalovirus infection8 works · 2 trials
Mantle cell lymphoma8 works · 9 trials
Dystonia6 works · 0 trials
Haemophilia6 works · 7 trials
Follicular lymphoma5 works · 15 trials
Chronic myeloid leukaemia5 works · 7 trials
ANCA-associated vasculitis5 works · 8 trials
Dermatomyositis and polymyositis (myositis)5 works · 6 trials
Sjögren's disease4 works · 13 trials
Aplastic anaemia4 works · 2 trials

Institution data: ROR 01hq89f96 (CC0-1.0)Updated 12 Nov 2026

Report an error